# M. Bagot

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/m-bagot/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,653 |
| Field | Cutaneous lymphoproliferative disorders research |
| h-index | 67 |
| i10-index | 278 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5068469347 |
| ORCID iD | https://orcid.org/0000-0002-1631-5192 |
| Works | 909 |

## Researcher papers

- [Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer](https://scholariq.org/papers/clinical-end-points-and-response-criteria-in-mycosis-fungoides-and-sezary/)
- [Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial](https://scholariq.org/papers/mogamulizumab-versus-vorinostat-in-previously-treated-cutaneous-t-cell-lymphoma/)
- [European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017](https://scholariq.org/papers/european-organisation-for-research-and-treatment-of-cancer-consensus/)
- [Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model](https://scholariq.org/papers/cutaneous-lymphoma-international-consortium-study-of-outcome-in-advanced-stages/)
- [EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*](https://scholariq.org/papers/eortc-iscl-and-usclc-consensus-recommendations-for-the-treatment-of-primary/)
- [Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder](https://scholariq.org/papers/increasing-comorbidities-suggest-that-atopic-dermatitis-is-a-systemic-disorder/)
- [European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes](https://scholariq.org/papers/european-dermatology-forum-s1-guideline-on-the-diagnosis-and-treatment-of/)

## Researcher topics

- [Cutaneous lymphoproliferative disorders research](https://scholariq.org/topics/cutaneous-lymphoproliferative-disorders-research/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Fungal Infections and Studies](https://scholariq.org/topics/fungal-infections-and-studies/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.